David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
J Exp Med. 2019 May 6;216(5):1005-1009. doi: 10.1084/jem.20190609. Epub 2019 Apr 26.
With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.
目前正在进行超过 40 项临床试验，我们即将迎来首个获得 FDA 批准的活体微生物治疗药物。麻省理工学院和哈佛医学院助理教授 Giovanni Traverso 及其同事 Miguel Jimenez 和麻省理工学院学院教授 Robert Langer 讨论了向患者施用活体微生物的重大挑战，以及这些新的复杂治疗药物的药物输送机会。
